EN
/
JP
News
About Us
About Us
Philosophy/Policy
Board of Directors
History
Company Information
Corporate Governance
Partner
Close
Business Strategy
Business Strategy
Business Model
Life Cycle Management Strategy
Close
Technology
Technology
SLC Transporters
LAT1 Inhibitors
Close
Pipeline
Pipeline
Development Status
Biliary Tract Cancer
Multiple Sclerosis
Other Pipelines
Close
Clinical Trials
Clinical Trials
Biliary Tract Cancer Phase III
JPH034 Phase 1
Close
IR
IR
IR News
Top Message
Disclosure Policy
Financial Highlights
IR Calendar
IR Library
Financial Results
Presentation Materials
IR Materials
Stock Information
Stock Overview
General Meeting of Shareholders
Disclaimer
Close
Contact
EN
/
JP
Close
Top
＞
News Lists
News Lists
All
2026
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2020.06.25
Hitoshi Endou, MD, Ph.D., Steps Down as Chairman & Representative Director and Takes Up the Title of Founder & Fellow of J-Pharma Co., Ltd.
2019.12.24
A specific clinical study of PET probes conducted by a group led by Assistant Professor Watanabe of Osaka University
2019.04.25
Conclusion of Licensing and Joint Development Contract for Novel Agent for Biliary Tract Cancer
2018.12.12
Hitoshi Endo has been appointed as Executive Chairman and Masuhiro Yoshitake has been appointed as President & CEO.
2018.07.19
Started Phase II clinical trial of JPH203 in Japan
2018.05.23
JPH203 Phase I result will be presented at ASCO Annual Meeting
2018.03.29
Announcement of in-license agreement for a candidate compound of novel anticancer drug which inhibits amino acid transporter-1 (LAT1)
2018.01.19
Completion of Phase I clinical trial of novel anti-cancer agent JPH203
2017.09.11
Joint research agreement with Osaka University on a novel PET probe (NKO 028)
2016.05.10
Granting of uric acid transporter URAT1 patent to AstraZeneca group
1
2
3
4
5
6
7
8
